Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (341-350 of 539) with videos related to

Pageof 54
Sort By:
Haematologica|June 29, 2023
Clonal hematopoiesis with <i>DNMT3A</i> and <i>PPM1D</i> mutations impairs regeneration in autologous stem cell transplant recipientsPatrick Stelmach, Sarah Richter, Sandra Sauer, et al.
Haematologica|January 20, 2022
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilitiesNicola Giesen, Nagarajan Paramasivam, Umut H Toprak, et al.
British Journal of Cancer|March 4, 2018
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cellsAngelique Bruyer, Ken Maes, Laurie Herviou, et al.
The Oncologist|July 27, 2014
European perspective on multiple myeloma treatment strategies in 2014Heinz Ludwig, Pieter Sonneveld, Faith Davies, et al.
British Journal of Haematology|April 6, 2021
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trialTorben Plesner, Meletios A Dimopoulos, Albert Oriol, et al.
Cancer Treatment Reviews|September 25, 2010
Treatment of relapsed and refractory multiple myeloma in the era of novel agentsNiels W C J van de Donk, Henk M Lokhorst, Meletios Dimopoulos, et al.
Blood|April 23, 2013
Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6Mathias Witzens-Harig, Dirk Hose, Simone Jünger, et al.
Haematologica|June 7, 2021
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patientsNiels Weinhold, Hans J Salwender, David A Cairns, et al.
Transplantation|November 16, 2005
Indications for liver transplantation in patients with amyloidosis: a single-center experience with 11 casesReinhard Singer, Arianeb Mehrabi, Peter Schemmer, et al.
Ejhaem|October 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myelomaStefan Knop, Monika Szarejko, Norbert Grząśko, et al.
Pageof 54

Showing results (341-350 of 539) with videos related to

Sort By:
Pageof 54
Haematologica|June 29, 2023
Clonal hematopoiesis with <i>DNMT3A</i> and <i>PPM1D</i> mutations impairs regeneration in autologous stem cell transplant recipientsPatrick Stelmach, Sarah Richter, Sandra Sauer, et al.
Haematologica|January 20, 2022
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilitiesNicola Giesen, Nagarajan Paramasivam, Umut H Toprak, et al.
British Journal of Cancer|March 4, 2018
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cellsAngelique Bruyer, Ken Maes, Laurie Herviou, et al.
The Oncologist|July 27, 2014
European perspective on multiple myeloma treatment strategies in 2014Heinz Ludwig, Pieter Sonneveld, Faith Davies, et al.
British Journal of Haematology|April 6, 2021
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trialTorben Plesner, Meletios A Dimopoulos, Albert Oriol, et al.
Cancer Treatment Reviews|September 25, 2010
Treatment of relapsed and refractory multiple myeloma in the era of novel agentsNiels W C J van de Donk, Henk M Lokhorst, Meletios Dimopoulos, et al.
Blood|April 23, 2013
Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6Mathias Witzens-Harig, Dirk Hose, Simone Jünger, et al.
Haematologica|June 7, 2021
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patientsNiels Weinhold, Hans J Salwender, David A Cairns, et al.
Transplantation|November 16, 2005
Indications for liver transplantation in patients with amyloidosis: a single-center experience with 11 casesReinhard Singer, Arianeb Mehrabi, Peter Schemmer, et al.
Ejhaem|October 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myelomaStefan Knop, Monika Szarejko, Norbert Grząśko, et al.
Pageof 54